Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more
Actinogen Medical Limited (ATGGF) - Total Liabilities
Latest total liabilities as of June 2025: $6.15 Million USD
Based on the latest financial reports, Actinogen Medical Limited (ATGGF) has total liabilities worth $6.15 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Actinogen Medical Limited - Total Liabilities Trend (2008–2025)
This chart illustrates how Actinogen Medical Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Actinogen Medical Limited Competitors by Total Liabilities
The table below lists competitors of Actinogen Medical Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Geox S.p.A
PINK:GXSBF
|
USA | $594.19 Million |
|
Leenos Corp
KQ:039980
|
Korea | ₩11.99 Billion |
|
Katahdin Bankshares Corp
OTCQX:KTHN
|
USA | $991.47 Million |
|
Som Distilleries & Breweries Limited
NSE:SDBL
|
India | ₹5.61 Billion |
|
Bogazici Beton Sanayi ve Ticaret AS
IS:BOBET
|
Turkey | TL5.89 Billion |
|
Long Bon International Co Ltd
TW:2514
|
Taiwan | NT$18.63 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Actinogen Medical Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Actinogen Medical Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Actinogen Medical Limited (2008–2025)
The table below shows the annual total liabilities of Actinogen Medical Limited from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $6.15 Million | +280.42% |
| 2024-06-30 | $1.62 Million | -10.34% |
| 2023-06-30 | $1.80 Million | +15.01% |
| 2022-06-30 | $1.57 Million | +70.21% |
| 2021-06-30 | $920.32K | -12.16% |
| 2020-06-30 | $1.05 Million | +87.96% |
| 2019-06-30 | $557.39K | -27.45% |
| 2018-06-30 | $768.25K | -9.00% |
| 2017-06-30 | $844.26K | +2.43% |
| 2016-06-30 | $824.20K | +270.20% |
| 2015-06-30 | $222.64K | +345.93% |
| 2014-06-30 | $49.93K | -38.60% |
| 2013-06-30 | $81.32K | -31.55% |
| 2012-06-30 | $118.81K | +25.48% |
| 2011-06-30 | $94.68K | -45.45% |
| 2010-06-30 | $173.58K | +64.66% |
| 2009-06-30 | $105.42K | +28.04% |
| 2008-06-30 | $82.33K | -- |